INTRODUCTION
Vasculitis is a term used for a heterogeneous group of clinical conditions with a common feature of vessel inflammation and is characterized by fibrinoid necrosis, thrombosis, and sometimes a granulomatous reaction. Vascular damage may occur in venules, capillaries, and arterioles, causing local and systemic clinical manifestations, depending on the organs involved, thus presenting with varied signs and symptoms. [1] Leukocytoclastic vasculitis (LCV), also referred as hypersensitivity vasculitis and hypersensitivity angiitis, is a histopathologic term commonly used to denote a small-vessel vasculitis. Patients with LCV generally have a good prognosis; however, if kidneys, gastrointestinal tract, lungs, heart, or central nervous system are involved, morbidity may increase and mortality can occur. Cutaneous lesions of LCV are mostly asymptomatic, but they may be associated with pruritus or pain. Bullous lesions, as well as chronic cutaneous disease, may involve ulceration or painful episodes of purpura, which confluent, palpable erythematous nonblanchable purpura. On history elicitation, the patient reported being diagnosed with paranoid schizophrenia (Diagnostic and Statistical Manual of Mental Disorders [DSM]-IV) 8 years ago, for which he was admitted and was treated with haloperidol (2 mg intravenous [IV]) along with benztropine 1 mg IV, divalproex sodium 500 mg once daily (OD), and lorazepam 4 mg IV. At the time of discharge, for about 2 weeks, the patient was continued on oral haloperidol 5 mg twice daily and divalproex sodium 500 mg OD. After 7 years of therapy with haloperidol, he developed typical choreiform and athetoid bucco-oro-masticatory movements characterized by lip smacking, puffing of cheeks, and fly catching motion of tongue. A provisional diagnosis of tardive dyskinesia, based on the DSM-V criteria, was made, and a dose of haloperidol was tapered. With nonresolvement of symptoms in subsequent visits, haloperidol was finally discontinued and clozapine was initiated 17 days earlier to the present date of reporting. His dose was slowly uptitrated. When the total dose of clozapine was 137.5 mg/day, he developed this rash on his legs. The rash continued to spread up to his lower extremities. He was afebrile with stable vital signs and had a benign examination otherwise.
The initial differential diagnoses included Rocky Mountain spotted fever, Churg-Strauss syndrome, Wegener's granulomatosis, microscopic polyarteritis, mixed cryoglobulinemia, and Henoch-Schönlein purpura. The patient was empirically administered doxycycline in case of Rocky Mountain spotted fever, and his divalproex sodium and clozapine doses were held steady. Rocky Mountain spotted fever was ruled out by serology. Churg-Strauss syndrome was unlikely because he did not have a history of asthma or eosinophilia. The results of urine and blood cultures and serologies consisting of complete blood count, liver function tests, creatine kinase, and erythrocyte sedimentation rate were all under the routine limits. He was managed conservatively without steroids and underwent further serological testing including serum cryoglobulins, complement C3, complement C4, hepatitis C, and antineutrophil cytoplasmic antibodies tests, whose results were found negative. Histopathology shows subepidermal blister with vascular damage affecting mainly small vessels of the dermis and is characterized by predominately neutrophilic infiltrate along other mononuclear infiltrate, and there is fragmentation of nuclei (karyorrhexis), with swelling of endothelial cells with fibrin deposit, suggestive of LCV [ Figures 1 and 2 ]. Since clozapine was the only recently added medication, a physician decided to dechallenge this medication. The patient gradually improved with conservative management. However, no rechallenge was attempted. The temporal relationship between clozapine and small-vessel vasculitis was thus made.
Causality assessment of the reaction conferred it to be "probable" with a score of 5 using Naranjo's causality assessment algorithm, [8] while the WHO-UMC causality assessment scale [9] graded it as probable or likely. Severity assessment using Hartwig-Siegels Scale [10] conferred it to be moderate (Level 4). The event was reported under the Pharmacovigilance Programme of India.
DISCUSSION
Small-vessel vasculitis refers to inflammation in the walls of the small vessels. Conventionally, these are cutaneous blood vessels. The classic phenotypic manifestation of small-vessel vasculitis is palpable purpura; however, this is often not present. The histopathologic features of the vessel wall inflammation are important in defining the nature of the vasculitis. [11] The hallmark histopathologic pattern of small-vessel vasculitis is LCV; however, a lymphocytic form has also been described whose etiology or clinical relevance is still unclear. [11] During the initial disease phase, monocytes and plasmocytes remain the predominant infiltrates without fibrinoid necrosis or the nuclear fragments, a characteristic of LCV. [12] Old lesions of small-vessel vasculitis may no longer demonstrate LCV and may contain mainly lymphocytes around blood vessels. This later consideration stresses the importance of the timing when taking a biopsy in a dynamic process such as the vasculitic one.
LCV is characterized by angiocentric segmental inflammation, endothelial cell swelling, fibrinoid necrosis of blood vessel walls, and a cellular infiltrate around and within dermal blood vessel walls composed largely of the neutrophils showing the fragmentation of the nuclei. Erythrocyte extravasation is another key feature. [13] The clinical picture of vasculitis is majorly dependent on the extent of vascular bed involvement, delay in diagnosis, and treatment. These heterogeneous clinical The duration between exposure to a causative agent and subsequent development of vasculitis is extremely variable, ranging from hours to years. It is, therefore, difficult to ascertain an exact period after which drug-induced vasculitis is likely to commonly manifest. In most instances, however, the onset of drug-induced vasculitis typically occurs from 1 to 3 weeks after drug initiation. It is imperative for clinicians to be aware that drug-induced vasculitis can occur after increasing the dose of a medication or a rechallenge of the offending drug. [14, 15] Prompt withdrawal of the offending drug may resolve the severity to the possible extent.
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